Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 22Neoplasm Metastasis 2Uveal Melanoma 1Skin Neoplasms 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Renal Cell 1

Interventions

Ipilimumab 29Nivolumab 23pembrolizumab 14incomplete Freund's adjuvant 10Cyclophosphamide 10Melphalan 9Interleukin-2 9CTLA-4 Antigen 8tebentafusp 7sargramostim 7Temozolomide 7MART-1 Antigen 7Dacarbazine 7Ranibizumab 6montanide ISA 51 5fludarabine phosphate 5fludarabine 5Sunitinib 5Radiosurgery 5Carboplatin 5Blood Specimen Collection 5Bevacizumab 5aldesleukin 4aflibercept 4Surveys and Questionnaires 4Magnetic Resonance Spectroscopy 4Granulocyte-Macrophage Colony-Stimulating Factor 4Biopsy 4trametinib 3sotrastaurin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × Interferon alpha-2 × Dermatologic × Clear all
NCT01100528 2019-02-26

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Case Comprehensive Cancer Center

Phase 2 Completed
38 enrolled 10 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡